Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China

Hao Zhang; Jingwen Tan; Dimitrios P. Kontoyiannis; Yabin Zhou; Weixia Liu; Pengfei Zhu; Xiuyan Shi; Zhe Wan; Ruoyu Li; Wei Liu

doi:10.1016/j.diagmicrobio.2019.05.003

Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China

Hao Zhang, Jingwen Tan, Dimitrios P. Kontoyiannis, Yabin Zhou, Weixia Liu, Pengfei Zhu, Xiuyan Shi, Zhe Wan, Ruoyu Li, Wei Liu

Infectious Diseases, Infection Control, and Employee Health

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The present study was to determine the in vitro activity of posaconazole (POS) against 385 Candida and 268 Aspergillus clinical isolates from China. We found that POS was active against 85.5% Candida and 94.4% Aspergillus isolates. Non–wild-type (non-WT) phenotype was found in a subset of Candida albicans (15.4%), Candida tropicalis (11.9%), Aspergillus fumigatus (4.1%), and Aspergillus flavus (17.4%) isolates. Cross-resistance to POS and other triazoles was seen. Gene sequencing showed that 4 C. albicans, 1 C. tropicalis, and 9 A. fumigatus isolates with cross-resistance to POS and other triazoles had mutations in ERG11 or CYP51A. In conclusion, POS has potent in vitro activity against most of Candida and Aspergillus isolates from China. Non-WT phenotype and those with cross-resistance to POS and other triazoles exist, frequently driven by mutations of ERG11 in Candida spp. and CYP51A in Aspergillus spp.

Original language	English (US)
Pages (from-to)	166-170
Number of pages	5
Journal	Diagnostic Microbiology and Infectious Disease
Volume	95
Issue number	2
DOIs	https://doi.org/10.1016/j.diagmicrobio.2019.05.003
State	Published - Oct 2019

Keywords

Aspergillus spp.
Candida spp.
Posaconazole
Susceptibility

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.diagmicrobio.2019.05.003

Cite this

Zhang, H., Tan, J., Kontoyiannis, D. P., Zhou, Y., Liu, W., Zhu, P., Shi, X., Wan, Z., Li, R., & Liu, W. (2019). Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China. Diagnostic Microbiology and Infectious Disease, 95(2), 166-170. https://doi.org/10.1016/j.diagmicrobio.2019.05.003

Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China. / Zhang, Hao; Tan, Jingwen; Kontoyiannis, Dimitrios P. et al.
In: Diagnostic Microbiology and Infectious Disease, Vol. 95, No. 2, 10.2019, p. 166-170.

Research output: Contribution to journal › Article › peer-review

Zhang, H, Tan, J, Kontoyiannis, DP, Zhou, Y, Liu, W, Zhu, P, Shi, X, Wan, Z, Li, R & Liu, W 2019, 'Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China', Diagnostic Microbiology and Infectious Disease, vol. 95, no. 2, pp. 166-170. https://doi.org/10.1016/j.diagmicrobio.2019.05.003

@article{5e7ef56081d143cfad335573cc090462,

title = "Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China",

abstract = "The present study was to determine the in vitro activity of posaconazole (POS) against 385 Candida and 268 Aspergillus clinical isolates from China. We found that POS was active against 85.5% Candida and 94.4% Aspergillus isolates. Non–wild-type (non-WT) phenotype was found in a subset of Candida albicans (15.4%), Candida tropicalis (11.9%), Aspergillus fumigatus (4.1%), and Aspergillus flavus (17.4%) isolates. Cross-resistance to POS and other triazoles was seen. Gene sequencing showed that 4 C. albicans, 1 C. tropicalis, and 9 A. fumigatus isolates with cross-resistance to POS and other triazoles had mutations in ERG11 or CYP51A. In conclusion, POS has potent in vitro activity against most of Candida and Aspergillus isolates from China. Non-WT phenotype and those with cross-resistance to POS and other triazoles exist, frequently driven by mutations of ERG11 in Candida spp. and CYP51A in Aspergillus spp.",

keywords = "Aspergillus spp., Candida spp., Posaconazole, Susceptibility",

author = "Hao Zhang and Jingwen Tan and Kontoyiannis, {Dimitrios P.} and Yabin Zhou and Weixia Liu and Pengfei Zhu and Xiuyan Shi and Zhe Wan and Ruoyu Li and Wei Liu",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = oct,

doi = "10.1016/j.diagmicrobio.2019.05.003",

language = "English (US)",

volume = "95",

pages = "166--170",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China

AU - Zhang, Hao

AU - Tan, Jingwen

AU - Kontoyiannis, Dimitrios P.

AU - Zhou, Yabin

AU - Liu, Weixia

AU - Zhu, Pengfei

AU - Shi, Xiuyan

AU - Wan, Zhe

AU - Li, Ruoyu

AU - Liu, Wei

PY - 2019/10

Y1 - 2019/10

N2 - The present study was to determine the in vitro activity of posaconazole (POS) against 385 Candida and 268 Aspergillus clinical isolates from China. We found that POS was active against 85.5% Candida and 94.4% Aspergillus isolates. Non–wild-type (non-WT) phenotype was found in a subset of Candida albicans (15.4%), Candida tropicalis (11.9%), Aspergillus fumigatus (4.1%), and Aspergillus flavus (17.4%) isolates. Cross-resistance to POS and other triazoles was seen. Gene sequencing showed that 4 C. albicans, 1 C. tropicalis, and 9 A. fumigatus isolates with cross-resistance to POS and other triazoles had mutations in ERG11 or CYP51A. In conclusion, POS has potent in vitro activity against most of Candida and Aspergillus isolates from China. Non-WT phenotype and those with cross-resistance to POS and other triazoles exist, frequently driven by mutations of ERG11 in Candida spp. and CYP51A in Aspergillus spp.

AB - The present study was to determine the in vitro activity of posaconazole (POS) against 385 Candida and 268 Aspergillus clinical isolates from China. We found that POS was active against 85.5% Candida and 94.4% Aspergillus isolates. Non–wild-type (non-WT) phenotype was found in a subset of Candida albicans (15.4%), Candida tropicalis (11.9%), Aspergillus fumigatus (4.1%), and Aspergillus flavus (17.4%) isolates. Cross-resistance to POS and other triazoles was seen. Gene sequencing showed that 4 C. albicans, 1 C. tropicalis, and 9 A. fumigatus isolates with cross-resistance to POS and other triazoles had mutations in ERG11 or CYP51A. In conclusion, POS has potent in vitro activity against most of Candida and Aspergillus isolates from China. Non-WT phenotype and those with cross-resistance to POS and other triazoles exist, frequently driven by mutations of ERG11 in Candida spp. and CYP51A in Aspergillus spp.

KW - Aspergillus spp.

KW - Candida spp.

KW - Posaconazole

KW - Susceptibility

UR - http://www.scopus.com/inward/record.url?scp=85066467148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066467148&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2019.05.003

DO - 10.1016/j.diagmicrobio.2019.05.003

M3 - Article

C2 - 31174994

AN - SCOPUS:85066467148

SN - 0732-8893

VL - 95

SP - 166

EP - 170

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 2

ER -

Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this